Drug Profile
RBB 003
Alternative Names: RBB-003Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Rubicon Biotechnology
- Class Anti-ischaemics; Antidotes; Recombinant fusion proteins
- Mechanism of Action Apoptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myocardial infarction; Poisoning
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Poisoning in USA (Inhalation) (Rubicon Biotechnology pipeline, September 2023)
- 15 Sep 2023 Discontinued for Myocardial infarction in USA (Parenteral) (Rubicon Biotechnology pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Poisoning in USA (Inhalation, Aerosol)